Fuqiang Hu

Dr. Fuqiang Hu

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2005 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
Fuqiang HuFuqiang Hu
Fuqiang Hu
SJSai-Ping Jiang
Sai-Ping Jiang
YDYong-Zhong Du
Yong-Zhong Du
HYHong Yuan
Hong Yuan
YYYi-Qing Ye
Yi-Qing Ye
SZSu Zeng
Su Zeng

28 February 2022 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
YZYingping Zeng
Yingping Zeng
SLSufen Li
Sufen Li
SZShufen Zhang
Shufen Zhang
LWLi Wang
Li Wang
HYHong Yuan
Hong Yuan
Fuqiang HuFuqiang Hu
Fuqiang Hu
Cancer immunotherapy can effectively inhibit cancer progression by activating the autoimmune system, with low toxicity and high effectiveness. Some of cancer immunotherapy had positive effects on clinical cancer treatment. However, cancer immunotherapy is still restricted by cancer heterogeneity, immune cell disability, tumor immunosuppressive microenvironment and systemic immune toxicity. Cell membrane-coated nanoparticles (CMCNs) inherit abundant source cell-relevant functions, including “self” markers, cross-talking with the immune system, biological targeting, and homing to specific regions. These enable them to possess preferred characteristics, including better biological compatibility, weak immunogenicity, immune escaping, a prolonged circulation, and tumor targeting. Therefore, they are applied to precisely deliver drugs and promote the effect of cancer immunotherapy. In the review, we summarize the latest researches of biomimetic CMCNs for cancer immunotherapy, outline the existing specific cancer immune therapies, explore the unique functions and molecular mechanisms of various cell membrane-coated nanoparticles, and analyze the challenges which CMCNs face in clinical translation.

5 April 2013 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
YHYuan Hong
Yuan Hong
CCChun-Yan Chen
Chun-Yan Chen
Guihong ChaiGuihong Chai
Guihong Chai
YDYong-Zhong Du
Yong-Zhong Du
Fuqiang HuFuqiang Hu
Fuqiang Hu

1 May 2006 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Fuqiang HuFuqiang Hu
Fuqiang Hu
SJSai-Ping Jiang
Sai-Ping Jiang
YDYong-Zhong Du
Yong-Zhong Du
HYHong Yuan
Hong Yuan
YYYi-Qing Ye
Yi-Qing Ye
SZSu Zeng
Su Zeng

1 May 2015 in Journal of Controlled Release
Verified
Journal Article
Closed access
YHYing-Wen Hu
Ying-Wen Hu
YDYong-Zhong Du
Yong-Zhong Du
NLNa Liu
Na Liu
XLXuan Liu
Xuan Liu
TMTing-Ting Meng
Ting-Ting Meng
Fuqiang HuFuqiang Hu
Fuqiang Hu

1 July 2006 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
Fuqiang HuFuqiang Hu
Fuqiang Hu
GRGuo-Fei Ren
Guo-Fei Ren
HYHong Yuan
Hong Yuan
YDYong-Zhong Du
Yong-Zhong Du
SZSu Zeng
Su Zeng